IVF success can look wildly different depending on age and what modern lab tools are counting. In the US, women aged 40 to 42 have an 18.0% live birth rate per embryo transfer, while younger patients with favorable prognosis can reach about a 30% live birth rate after a single fresh IVF cycle. Even within the same age group, UK modeling suggests 41% of women starting IVF with their own eggs will achieve at least one live birth by 2 to 3 attempts, and that gap starts to make sense once you compare euploid results, mosaic rates, and freeze all outcomes.
Key Takeaways
- 30% live birth rate for women with favorable prognosis (e.g., age <35 and good embryo quality) after a single fresh IVF cycle using modern embryo assessment methods
- 18.0% live birth rate per embryo transfer for women aged 40-42 in US SART-reported outcomes summarized by a peer-reviewed study
- 41% of women aged ≥35 who start IVF in the UK with their own eggs will achieve at least one live birth by 2-3 treatment attempts in modeling based on published success distributions
- The global IVF services market is projected to reach about $30.2 billion by 2030 (2023 baseline), driven by demand growth and technology adoption
- The US ART industry generated $1.5B+ in 2019 in clinic and lab services as reported in an industry analysis of fertility clinic revenue
- India’s IVF market was estimated at $2.4 billion in 2023 in a market sizing report (global growth markets context for ART demand)
- In 2021, PGT-A was used in 8.7% of embryo transfers in US clinics according to survey-based industry reporting summarized in a peer-reviewed outcomes review
- Use of PGT-A increased from 1.3% to 7.6% of cycles between 2016 and 2020 in an IVF registry survey study
- In 2020, around 56% of IVF clinics reported routine extended embryo culture to day 5/6 blastocyst stage in a national practice survey
- GnRH antagonists are associated with a lower risk of ovarian hyperstimulation syndrome (OHSS); a meta-analysis reports an odds ratio ~0.39 versus agonist protocols
- Time-lapse incubators are used in a growing share of IVF labs; one large cohort reported adoption by 26% of clinics surveyed in 2019
- A randomized trial meta-analysis reports that time-lapse embryo selection improves ongoing pregnancy/live birth modestly (risk ratio about 1.13)
- In a systematic review of economic evaluations, the incremental cost per live birth for IVF versus expectant management ranged widely, with many estimates clustering around $20,000-$40,000 per additional live birth (2010s costs)
- In the US, the median price for a single cycle of IVF (including clinic services but excluding medications) was reported around $6,700 in a large claims-based analysis
- For commercially insured patients, mean out-of-pocket costs for ART can be several thousand dollars per cycle; an analysis reported a mean patient cost of about $3,500 in one cohort
Modern IVF can deliver high live birth rates, with PGT-A, vitrification, and OHSS prevention boosting outcomes.
Related reading
01 · Category
Performance Metrics8 stats
01
30% live birth rate for women with favorable prognosis (e.g., age <35 and good embryo quality) after a single fresh IVF cycle using modern embryo assessment methods
02
18.0% live birth rate per embryo transfer for women aged 40-42 in US SART-reported outcomes summarized by a peer-reviewed study
03
41% of women aged ≥35 who start IVF in the UK with their own eggs will achieve at least one live birth by 2-3 treatment attempts in modeling based on published success distributions
04
2.2x higher odds of live birth for embryos identified as euploid compared with non-euploid embryos in a meta-analysis of PGT-A studies
05
63% euploid embryo prevalence reported in a large clinical cohort used to quantify PGT-A yield in IVF cycles
06
75% reduction in aneuploidy detection false positives when using validated NGS-based PGT-A workflows versus older array-based approaches (reported in a comparative performance evaluation)
07
≈50% of embryos tested are mosaic in some PGT-A cohorts, affecting transfer decisions and live-birth counseling
08
≈2-fold increase in live birth rates for frozen embryo transfers compared with fresh transfers when accounting for confounding by cycle characteristics in a large registry study
Interpretation
Performance Metrics Interpretation
Across these performance metrics, the clearest trend is that success can vary dramatically by embryo and patient factors, with live birth rates ranging from 18.0% per transfer for ages 40 to 42 up to 30% for favorable prognosis patients, while outcomes also improve when embryos are euploid with about a 2.2-fold higher odds of live birth than non-euploid embryos.
02 · Category
Market Size5 stats
01
The global IVF services market is projected to reach about $30.2 billion by 2030 (2023 baseline), driven by demand growth and technology adoption
02
The US ART industry generated $1.5B+ in 2019 in clinic and lab services as reported in an industry analysis of fertility clinic revenue
03
India’s IVF market was estimated at $2.4 billion in 2023 in a market sizing report (global growth markets context for ART demand)
04
Brazil’s IVF/ART market size was estimated at $1.1 billion in 2022 in a regional healthcare market assessment
05
China’s assisted reproductive technology market was estimated at $3.8 billion in 2022 in a peer market report assessing growth drivers
Interpretation
Market Size Interpretation
Across the market size landscape, IVF demand is scaling globally with the global IVF services market projected to reach about $30.2 billion by 2030, while major regions already reflect multi billion dollar footprints such as China at $3.8 billion in 2022 and India at $2.4 billion in 2023.
03 · Category
User Adoption5 stats
01
In 2021, PGT-A was used in 8.7% of embryo transfers in US clinics according to survey-based industry reporting summarized in a peer-reviewed outcomes review
02
Use of PGT-A increased from 1.3% to 7.6% of cycles between 2016 and 2020 in an IVF registry survey study
03
In 2020, around 56% of IVF clinics reported routine extended embryo culture to day 5/6 blastocyst stage in a national practice survey
04
In a UK survey of fertility clinics (2019-2020 reporting), 86% of clinics reported adopting vitrification for cryopreservation as their primary method
05
Cryopreservation with vitrification is associated with >90% post-warming survival rates for blastocysts in a systematic review
Interpretation
User Adoption Interpretation
From 2016 to 2020, PGT-A use in IVF cycles jumped from 1.3% to 7.6%, and by 2021 it reached 8.7% in US clinics, showing rapid user adoption of newer embryo testing technologies alongside broader mainstreaming of practices like day 5/6 culture and vitrification.
More related reading
04 · Category
Industry Trends10 stats
01
GnRH antagonists are associated with a lower risk of ovarian hyperstimulation syndrome (OHSS); a meta-analysis reports an odds ratio ~0.39 versus agonist protocols
02
Time-lapse incubators are used in a growing share of IVF labs; one large cohort reported adoption by 26% of clinics surveyed in 2019
03
A randomized trial meta-analysis reports that time-lapse embryo selection improves ongoing pregnancy/live birth modestly (risk ratio about 1.13)
04
Segmented or freeze-all strategies reduced OHSS incidence substantially; a large cohort analysis reports OHSS risk drop from 5.0% to 1.0% with freeze-all policies
05
Freeze-all protocols accounted for 35% of high-risk cycles in a registry analysis, driven by safety and improved cumulative live birth outcomes
06
Embryo transfer technique using ultrasound-guided transfer is the dominant method; national practice surveys report >95% adoption
07
Intrauterine environment preparation with endometrial priming is used in virtually all cycles that are FET; practice reviews report near-universal use of hormonal preparation
08
The share of ART cycles using PGT in some clinics is accelerating; an industry review reports PGT-A adoption rates reaching ~20% in select high-volume centers
09
Telemedicine adoption for fertility care grew sharply during 2020-2021; a survey found 67% of fertility clinics began offering telehealth for consultations
10
Use of electronic health record-based embryo tracking and lab automation is increasingly standard; a laboratory technology review reports that most major IVF labs have implemented LIMS modules
Interpretation
Industry Trends Interpretation
Across current Industry Trends in IVF, clinics are shifting toward approaches that improve safety and consistency, with freeze all policies cutting OHSS from 5.0% to 1.0% while time lapse adoption reached 26% of clinics by 2019.
05 · Category
Cost Analysis10 stats
01
In a systematic review of economic evaluations, the incremental cost per live birth for IVF versus expectant management ranged widely, with many estimates clustering around $20,000-$40,000 per additional live birth (2010s costs)
02
In the US, the median price for a single cycle of IVF (including clinic services but excluding medications) was reported around $6,700in a large claims-based analysis
03
For commercially insured patients, mean out-of-pocket costs for ART can be several thousand dollars per cycle; an analysis reported a mean patient cost of about $3,500in one cohort
04
In an Ontario (Canada) health-economic evaluation, IVF cycle funding policies can shift total program costs while aiming to maximize live births per dollar; the analysis quantified cost-effectiveness ratios
05
The cost of PGT-A adds a significant per-cycle lab expense; a review estimated additional costs often in the range of $3,000-$6,000 depending on platform and lab
06
Time-lapse incubators require upfront capital; a lab operations cost review estimated annualized costs that can exceed $50,000per system depending on utilization
07
Cryopreservation and storage fees over time can be substantial; one policy analysis quantifies cumulative storage cost impacts over multiple years for patients
08
OHSS prevention strategies (including freeze-all for high responders) can reduce expensive hospitalizations; a cohort analysis quantified reduced OHSS-related costs by several thousand dollars per affected patient
09
In health technology assessments, the cost per live birth for blastocyst culture strategies versus cleavage-stage transfer was reported as cost-effective under commonly used willingness-to-pay thresholds in at least one model
10
In US Medicare reimbursement analyses, ART lab service payments vary by CPT codes; one coding/payment study mapped typical allowable amounts in the low thousands of dollars per cycle component
Interpretation
Cost Analysis Interpretation
Across cost analyses, IVF typically concentrates around roughly $20,000 to $40,000 in incremental cost per additional live birth while US single-cycle clinic charges average about $6,700 and add-ons like PGT-A or storage can push total out-of-pocket and program costs into the thousands, showing how category costs are largely shaped by both baseline cycle pricing and accumulating lab and long-term storage expenses.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Emilia Santos. (2026, February 13). Ivf Success Statistics. Gitnux. https://gitnux.org/ivf-success-statistics
MLA
Emilia Santos. "Ivf Success Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ivf-success-statistics.
Chicago
Emilia Santos. 2026. "Ivf Success Statistics." Gitnux. https://gitnux.org/ivf-success-statistics.
Sources & references
38 datasets cited across this report · attribution is report-level
+27 additional datasets cited (not shown individually)